Overview

* Inspire Medical Q2 2025 revenue rises 11%, beating analyst expectations, per LSEG data

* Company reports net loss of $3.6 mln

* Launch of Inspire V system slower than expected, affecting financial outlook

Outlook

* Inspire lowers 2025 revenue guidance to $900 mln-$910 mln

* Company maintains 2025 gross margin guidance of 84%-86%

* Inspire expects 2025 diluted EPS of $0.40-$0.50

* Company cites slower U.S. launch of Inspire V for guidance cut

Result Drivers

* INSPIRE V LAUNCH - Full launch of Inspire V system in U.S. is a key milestone, but slower than expected, impacting financial results

* INVENTORY CHARGE - $2.1 mln charge due to excess components inventory related to Inspire IV

* OPERATING EXPENSES - Increased by 15% due to U.S. sales expansion, marketing, and legal costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $217.10 $214.30

Revenue mln mln (16

Analysts

)

Q2 EPS -$0.12

Q2 Net -$3.60

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Inspire Medical Systems Inc ( INSP ) is $210.00, about 40% above its August 1 closing price of $126.10

* The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 63 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)